Safety and efficacy of sargramostim (GM‐CSF) in the treatment of Alzheimer's disease

INTRODUCTION: Inflammatory markers have long been observed in the brain, cerebrospinal fluid (CSF), and plasma of Alzheimer's disease (AD) patients, suggesting that inflammation contributes to AD and might be a therapeutic target. However, non‐steroidal anti‐inflammatory drug trials in AD and m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alzheimers Dement (N Y)
Main Authors: Potter, Huntington, Woodcock, Jonathan H., Boyd, Timothy D., Coughlan, Christina M., O'Shaughnessy, John R., Borges, Manuel T., Thaker, Ashesh A., Raj, Balaibail A., Adamszuk, Katarzyna, Scott, David, Adame, Vanesa, Anton, Paige, Chial, Heidi J., Gray, Helen, Daniels, Joseph, Stocker, Michelle E., Sillau, Stefan H.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7988877/
https://ncbi.nlm.nih.gov/pubmed/33778150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/trc2.12158
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados